Monthly schizophrenia therapy ‘Abilify Maintena’ launched with insurance benefit

Published: 2016-09-02 11:03:11

Updated: 2016-09-02 11:03:30

A schizophrenia therapy whose patient drug compliance and recurrence control were improved compared to oral drugs, ‘Abilify Maintena’ will be launched this September.

Korea Otsuka Pharmaceuticals(CEO Seung-ho Moon) announced a plan to launch the drug with health insurance benefits at a press conference on the 31^st. Abilify Maintena is an injection which was modified in formulation from the bl...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.